This is a prospective, multicenter, randomized controlled (1:1) non-inferiority clinical trial. A total of 54 subjects are scheduled to be enrolled at no fewer than 2 study sites in China.

After providing written informed consent, all subjects will undergo screening assessments. Those who fully meet all inclusion criteria and satisfy none of the exclusion criteria will be enrolled in this clinical trial.

Inclusion Criteria:

1. Age 18 to 80 years (inclusive), gender unrestricted;
2. Patients with corneal blindness, unable to perform activities of daily living independently, and best-corrected visual acuity < 0.05 in both eyes;
3. Patients with a high expected risk of failure of allogeneic corneal transplantation or high surgical risk for corneal transplantation;
4. Relatively stable primary ocular diseases, no active purulent infection, and general condition sufficient to tolerate surgery;
5. Normal intraocular pressure, or stable intraocular pressure after treatment for glaucoma (IOP < 21 mmHg);
6. Normal structure and function of the retina and optic nerve, with preserved visual potential;
7. Willing to participate in this study and have signed the written informed consent form.

Exclusion Criteria:

1. Patients with poorly controlled intraocular pressure or requiring IOP-lowering medication, assessed as ineligible for surgery.
2. Patients with active conjunctival infection in the affected eye, assessed as unable to tolerate surgery.
3. Patients with unhealed wound following allogeneic penetrating keratoplasty.
4. Patients with anatomical abnormalities such as eyelid atresia or requiring a prosthetic device to penetrate the skin.
5. Patients with severely impaired retinal or optic nerve function with no potential for visual improvement.
6. Patients with a history of malignant tumor in or around the eye, judged ineligible by the investigator.
7. Patients with intolerance to local anesthetics, mydriatics, or device components, judged ineligible by the investigator.
8. Patients with severe diseases of major organs including heart, liver, and kidney, judged ineligible by the investigator.
9. Patients with severe coagulation disorders, judged ineligible by the investigator.
10. Patients with absolute glaucoma, judged ineligible by the investigator.
11. Patients with severe systemic diseases and a life expectancy of < 2 years.
12. Pregnant or lactating females.
13. Patients who do not understand the risks of keratoprosthesis surgery, cannot comply with regular follow-up, or fail to administer medication as required.
14. Other patients considered ineligible for this clinical trial by the investigator.